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Genetic Variants in Melanomars12203592 falls within an enhancer
region of IRF4; the T allele impairs
transcription factor binding, leading to
reduced expression of IRF4 and tyrosi-
nase (Praetorius et al., 2013).
In a recent meta-analysis, the associa-
tion between rs12203592 polymorphism
and SCC was significant in dominant,
recessive, and codominant models (Wu
et al., 2016). The additive genetic model
was selected a priori for our study, but
exploration of the codominant model
confirmed the association between SCC
risk and the TT versusCCgenotype (HR¼
2.24, 95% confidence interval ¼
1.22e4.09, P ¼ 0.009).
Previous studies investigating genetic
risks for cSCC in OTRs have been
limited by small sample sizes and
candidate gene approach; the recent
GWAS for cSCC has informed our
candidate gene selection in this cohort.
Our study design enabled investigation
of these genes in the context of Fitzpa-
trick skin type, an important risk factor.
Our data show that genotype data can
improve risk stratification for post-
transplantation cSCC beyond the clin-
ical pigmentation phenotype.
Strengths of this study include a well-
characterized cohort with Fitzpatrick
type and histopathologic confirmation
of cSCC outcomes. The genotyping
array is the same as that used in Asgari
et al. (2016), allowing direct validation
of SNPs reported in that publication.
The primary limitation is small sample
size, but this pilot data supports devel-
opment of cohort studies to generateAbbreviations: GWAS, genome-wide association stud
Anderson Cancer Center; MELARISK, the French Mel
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The most influential standard prog-
nostic factor for melanoma is Breslowthickness (thickness). Tissue micro-
arrays (TMAs) have identified thickness
biomarkers, including RGS1 (Rangelet al., 2008), ING4 (Li et al., 2008),
and total/atypical nevi (Geller et al.,
2016). In TMA, 23 of 24 DNA
repair genes were upregulated with
increasing thickness, whereas genes
involved in serine-type endopeptidase
inhibitor activity, cell adhesion, cell-
cell signaling, and transcription
factor activity were downregulated
(Winnepenninckx et al., 2006).www.jidonline.org 253
Table 1. Tumor-thickness-related SNPs in MDACC and MELARISK studies and their association with melanoma outcome
SNP Chr Position1
Nearby
Gene
Effect
allele
Tumor thickness
Association with melanoma
outcome in MDACC
MDACC MELARISK Heterogeneity4
Random-effects
Meta-analysis5 P-value
EAF2 b3 se3 P EAF2 b3 se3 P I2 [95% CI] Cochran b rand serand P rand
Stage
(III/VI
vs. I/II) MSS OS6 DFS7
rs7526389 1 119,616,604 WARS2/
HAO2
A 0.50 0.07 0.01 3.7  107 e e e e 0.16 0.79 1.00 0.90
rs1539188 1 119,630,065 WARS2/
HAO2
C 0.49 0.07 0.01 8.3  107 0.47 0.05 0.02 6.8  103 96.3
[89.9e98.7]
1.8  107 0.01 0.06 0.84 0.19 0.69 0.89 0.86
rs12365253 11 1,106,034 MUC2/
MUC5AC
C 0.79 0.10 0.02 5.6  108 e e e e 0.42 0.05 0.02 0.39
rs6421966 11 1,116,979 MUC2/
MUC5AC
G 0.19 0.09 0.02 3.2  107 0.17 0.00 0.02 0.97 89.8
[62.3e97.2]
1.8  103 0.05 0.05 0.31 0.65 1.6  103 9  104 0.16
rs7130988 11 1,119,721 MUC2/
MUC5AC
A 0.81 0.09 0.02 4.6  107 0.83 0.00 0.02 0.98 89.4
[60.7e97.2]
2.1  103 0.05 0.05 0.31 0.63 4.4  103 4.1  103 0.98
rs7112954 11 1,127,086 MUC2/
MUC5AC
C 0.81 0.10 0.02 4.7  107 0.84 0.00 0.02 0.85 90.8
[66.9e97.4]
1.0  103 0.05 0.05 0.35 0.55 2.7  103 2.7  103 0.98
rs17859811 11 1,140,353 MUC2/
MUC5AC
A 0.18 0.10 0.02 1.2  107 0.16 0.01 0.03 0.71 90.8
[67.1e97.4]
9.6  104 0.05 0.06 0.39 0.13 1  104 2  104 0.16
rs1049481 19 12,915,781 CALR G 0.39 0.08 0.02 5.8  107 0.42 0.01 0.02 0.44 84.6
[37e96.2]
0.01 0.05 0.03 0.13 0.04 0.05 0.12 0.03
rs2974755 19 12,923,663 RAD23A C 0.39 0.07 0.02 7.6  107 0.41 0.02 0.02 0.35 81.9
[23.3e95.7]
0.02 0.05 0.03 0.095 0.03 0.07 0.13 0.02
Note that the single nucleotide polymorphisms (SNPs) rs7526389 and rs12365253 were not present in the HapMap3 imputation panel used for French MELRISK study.
Abbreviations: Chr, chromosome; CI, confidence interval; DFS, disease-free survival; MDACC, MD Anderson Cancer Center; MELARISK, the French Melanoma Risk study; MSS, melanoma-specific survival; OS,
overall survival; SNP, single nucleotide polymorphisms.
1Position in base pair according to the genome build 36.3.
2EAF: effect allele frequency.
3b and se are the regression coefficient and standard error of the SNP effect, respectively, estimated by linear regression assuming an additive model.
4The I2 heterogeneity measure is the percentage of variation in study estimates that is due to heterogeneity. Cochran is the P-value of Cochran’s test for heterogeneity.
5brand and serand are the regression coefficient and standard error of the SNP effect, respectively, in the meta-analysis of MDACC and MELARISK (using a random-effects model). Prand is the P-value associated with
the Wald test of the meta-analyzed SNP effect.
6P-values for those significant SNPs for OS with adjustment for sex, age, and thickness: rs12365253 P ¼ 0.27, rs6421966 P ¼ 0.05, rs7130988 P ¼ 0.02, rs7112954 P ¼ 0.02, rs17859811 P ¼ 0.22.
7P-values for those significant SNPs for DFS with adjustment for sex, age, and thickness: rs1049481 P ¼ 0.11, rs2974755 P ¼ 0.09.
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Figure 1. Immunohistochemical (IHC) staining for MUC2 gene expression across primary-tumor-thickness groups and metastatic tumors. Upper left three
plots were primary tumors; Breslow tumor thickness (a) ¼ 1.35 mm, (b) ¼ 2.8 mm, (c) ¼ 10 mm. All scale bars ¼ 10 mm in the figures.
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Genetic Variants in MelanomaReduced gene dosage across 9p21.3,
including CDKN2B, P14ARF, and
CDKN2A, was associated with
increased thickness (Conway et al.,
2010). Finally, association has been
reported between thickness and
vitamin D receptor gene poly-
morphisms (Santonocito et al., 2007).
To better understand genes involved
in determining thickness and evaluate
contributions of genetic variation to
melanoma disease severity, we per-
formed a genome-wide association
study (GWAS) of thickness. Study pop-
ulations consisted of 1,804 patients with
melanoma from MD Anderson Cancer
Center (MDACC) (Amos et al., 2011)
and 966 patients from the French Mela-
noma Risk study (MELARISK) (Chaudru
et al., 2004). Populations and
genotyping methods are described in
Supplementary Texts S1 and S2 and
Supplementary Tables S1 and S2 online.
After imputation and quality control, we
had 2.65 million single nucleotide
polymorphisms (SNPs) in MDACC and1.05 million SNPs in MELARISK. All in-
dividuals provided written, informed
consent under an institutional review
board-approved protocol.
We confirmed that thickness repre-
sented an independent risk factor for
disease-free survival, overall survival,
and melanoma-specific survival after
adjustment for sex, age, and disease
stage (Supplementary Tables S3 and S4
online). The independent association
between thickness and overall survival
was replicated in MELARISK (hazard
ratio ¼ 1.11, 95% confidence
interval ¼ 1.07e1.16, Supplementary
Table S4); disease-free survival and
melanoma-specific survival were not
available in MELARISK.
Because the distribution of raw
thickness was skewed, we used the log-
arithm to base 10 of thickness for GWAS
(Supplementary Figure S1 online). The
Q-Q plot for MDACC is shown in
Supplementary Figure S2 online.
MDACC GWAS results are shown in
Supplementary Figure S3 and Table S5online (P < 105). The 20 SNPs most
strongly associated with thickness
spanned four loci (1p12, 6q23, 8q22,
11p15, and 19p13; Table 1 and
Supplementary Table S5). The most sig-
nificant loci were close to mucin 2
(MUC2)/mucin 5AC (MUC5AC) and
calreticulin (CALR)/RAD23 homolog
A (RAD23A). The most significant
imputed SNP, rs12365253, was near
MUC2/MUC5AC and had a P-value of
5.6  108, close to the nominal
genome-wide significance level of 5.0
108. The most strongly associated SNP
was supported by concordant results for
genotyped SNPs in linkage disequilib-
riumwith it (r2¼ 0.7817with genotyped
SNP rs64211966, P-value 3.2  107).
The most significant genotyped SNP,
rs17859811, had a P-value of 1.2 
107, but was in moderate linkage
disequilibrium (r2 ¼ 0.53, D0 ¼ 0.84)
with rs12365253 (Supplementary
Figure S4 online). The most significant
imputed SNP, rs1049481, near CALR/
RAD23A, had a P-value of 5.8  107,www.jidonline.org 255
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256followed by a genotyped SNP,
rs2974755 (P ¼ 7.6  107). These two
variants were in strong linkage disequi-
librium (r2 ¼ 0.96, D0 ¼ 0.99;
Supplementary Figure S5 online). We
performed joint analysis of the most
significant genotyped SNPs rs17859811
in the MUC2/MUC5AC region and
rs2974755 in the CALR/RAD23A re-
gion, and observed that the P-value
decreased to 2.6  1012.
All five SNPs in the MUC2/MUC5AC
gene regions were in strong linkage
disequilibrium (r2  0.70 with the most
significant SNP rs12365253) and were
nominally associated with overall sur-
vival and melanoma-specific survival in
MDACC (all P-values < 0.05, Table 1,
Supplementary Table S6 online). Two
SNPs in the CALR/RAD23A region had
borderline significance for melanoma-
specific survival but were associated
with disease-free survival (P-value <
0.05, Table 1). After adjustment for
thickness these associations were less
significant, suggesting that any effect of
these loci on melanoma recurrence or
survival is at least partially mediated
through tumor thickness.
Top-associated SNPs were selected
for attempted replication (Table 1).
Neither of our two most strongly
associated loci (MUC2/MUC5AC
and CALR/RAD23A) were replicated
in MELARISK, and another SNP
(rs1539188) in the WARS2/HAO2 re-
gion was not replicated (MDACC P ¼
8.3  107, MELARISK P ¼ 6.8  103,
with opposite direction of effects in the
two studies. Furthermore, the joint ef-
fect of the two most significant MDACC
SNPs, rs17859811 (MUC2/MUC5AC)
and rs2974755 (CALR/RAD23A), was
not replicated (P ¼ 0.60).
We performed gene-based testing us-
ing Versatile Gene-based Association
Study (VEGAS) (Liu et al., 2010) and
found that MUC2 and MUC5AC were
significantly associated with tumor
thickness in MDACC (both P-values
reached the multiple testing corrected
threshold of 2.8 106, Supplementary
Table S7 online). Results also suggested
the association of CALR and RAD23A
with thickness in MDACC (P  105,
Supplementary Table S7). However,
none of these genes was replicated in
MELARISK (Supplementary Table S7).
Notably, previous pathway analysis for
melanoma risk in MDACC andJournal of Investigative Dermatology (2017), VolumMELARISK identified five pathways
(Brossard et al., 2015), among which
was the induction of the programmed
cell death pathway that includesMUC2
andMUC5AC. Furthermore,MUC2 and
MUC5AC were associated with
melanoma risk in both datasets
(Supplementary Table S8 online;
P-values for the best SNP in each gene
<0.05), indicating those genes may also
contribute to melanoma development.
We investigated expression of
MUC2/MUC5AC and CALR/
RAD23A in melanomas and nevi
(Supplementary Text S1). We also
investigated MUC2 expression in tu-
mors from 84 patients not included in
MDACC. Using immunohistochemistry
(IHC), we stained slides from 60 pri-
mary and 24 metastatic melanoma tu-
mors (none from the same patient). We
also stained TMAs containing 40
benign nevi and 12 primary melanoma
tumors. The GWAS, IHC, and TMA
cohorts had similar demographic dis-
tributions (mean age: GWAS 52.1, IHC
53.9, TMA 52.5; male percentage:
GWAS 58.7, IHC 59.3, TMA 62.7; P-
values > 0.05). Although MUC2 was
commonly expressed in primary mela-
nomas and metastases, we identified no
significant difference in MUC2 expres-
sion across thickness groups (Figure 1;
P ¼ 0.824, Supplementary Figure S6
online), or between primary tumors
and metastases (P ¼ 0.484,
Supplementary Figure S6). In TMA,
primary tumors demonstrated higher
expression of MUC2 than nevi (P ¼
0.025, Supplementary Figure S7 on-
line). mRNA analysis of 17 metastatic
tumors (12 regional, 5 distant)
(Supplementary Figure S8 online)
identified MUC2 mRNA in the majority
of melanoma tumors but no correlation
between mRNA expression and thick-
ness (Pearson correlation coefficient ¼
0.267, P ¼ 0.487; data not shown).
Finally, we confirmed MUC2 protein by
western blot of regional metastases
from two patients with melanoma
with high MUC2 expression by IHC
(Supplementary Figure S9 online).
In summary, top polymorphisms
associated with melanoma tumor
thickness from MDACC GWAS were
not replicated in external validation,
possibly due to population-based dif-
ferences (Supplementary Text S2).
However, MUC2 conferred risk fore 137development of melanoma in both
datasets, and MUC2 was commonly
expressed in both primary melanomas
and metastases. No association was
identified between the level of MUC2
expression and thickness. These studies
provide preliminary evidence suggest-
ing that MUC2 may confer risk for
melanoma susceptibility, tumor thick-
ness, and/or disease severity.
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Cutaneous T-cell lymphoma is
commonly manifested as skin-restricted
mycosis fungoides (MF) or Se´zary syn-
drome (SS), a leukemic variant charac-
terized by erythroderma and circulating
malignant CD4D T cells with features
of T helper T(h) type 2 cells (Kim et al.,
2005).
T-cell immunoreceptor with Ig and
ITIM domains (TIGIT) is a recentlyidentified co-inhibitory receptor
expressed on the cell surface of acti-
vated or regulatory T cells and natural
killer cells. Emerging data suggest that
TIGIT plays an inhibitory role by
down-regulating Th1 and Th17 while
enhancing Th2 immune responses
(Johnston et al., 2015; Joller et al.,
2014; Kourepini et al., 2016; Kurtulus
et al., 2015; Zhang et al., 2016). He-
lios is a transcription factor in theIkaros family present in regulatory T
cells. Like TIGIT, Helios has inhibitory
activity and plays a role in antitumor
immunity (Khaitan et al., 2016; Muto
et al., 2015; Sebastian et al., 2016).
The expression and role of Helios and
TIGIT in SS have not been explored,
but given the immunosuppressive
nature of the disease, both molecules
may potentially contribute to this
process.
We reported high expression of
FCRL3 on CD26e CD4DT cells in SS
patients with high blood tumor
burden. A microarray analysis of
global gene expression that identified
FCRL3 also showed significantly
increased expression of Helios in
CD4D cells from SS patients with highwww.jidonline.org 257
